A First in Human Study of TT5 in Single and Multiple Ascending Doses in Healthy Volunteers and Surgical Patients

Main inclusion criteria for Parts A and B: * Non-smoker for the confinement period of the study. * Medically healthy and without clinically significant abnormalities. * Negative screen for alcohol and drugs of abuse. * No history of psychiatric disorders. * Female participants of non-childbearing potential must be post-menopausal or surgically sterile at least 3 months prior to dosing. * Sexually active females of childbearing potential and non-sterile males must be willing to use an acceptable contraceptive method throughout the study. * Able to understand the study procedures and provide signed informed consent to participate in the study in English. Main exclusion criteria for Parts A and B: * History of clinically significant asthma, anaphylaxis, major medical, psychiatric illness or surgery. * Acute or chronic clinically relevant systemic disease or disorder. * Renal insufficiency * History of drug or alcohol consumption abuse. * Drinking excessive amounts of tea, coffee, chocolate and/or beverage containing caffeine. * Have used any investigational drug or participated in any clinical trial within 4 weeks prior to screening. * Unable to refrain from strenuous exercise. * Participant who has received blood or plasma derivatives, who had a surgery or who has given blood within 4 weeks prior to the screening visit or has planned to give blood or sperm within the 90 days following the study. * Pregnant or lactating female participant.